Kefah Mokbel: Beyond Thromboprophylaxis – Enoxaparin’s Emerging Anticancer Signal
Kefah Mokbel, Professor of Medicine (Honorary) at Cardiff University School of Medicine, shared a post on LinkedIn about a recent article by Sedat Carkit et al., published in Scientific Reports, adding:
“Beyond Thromboprophylaxis: Enoxaparin’s Emerging Anticancer Signal
A new study in Scientific Reports adds to the growing evidence that enoxaparin – long used simply to manage cancer-associated thrombosis – may have direct effects on tumour biology.
Using MDA-MB-231 (breast) and HepG2 (liver) cancer cell lines alongside non-cancerous HEK-293 controls, the authors treated cells with a range of enoxaparin concentrations and found:
- Significantly reduced viability in both cancer cell lines, with no cytotoxicity in normal cells
- Markedly increased apoptosis on TUNEL analysis
- Increased LC3/p62 expression, indicating activation of autophagy
- Differential inflammatory modulation – NF-κB rose in breast cancer cells alongside suppression of IL-6 and TNF-α, while liver cancer cells showed no significant inflammatory change
- Reduced extracellular 8-OHdG, suggesting less oxidative DNA damage
The selectivity – hitting cancer cells while sparing normal cells – is what makes this interesting. It’s in-vitro work, so it doesn’t change clinical practice today, but it strengthens the rationale for exploring enoxaparin’s role beyond thromboprophylaxis in oncology.”
Title: Enoxaparin induces apoptosis and autophagy, modulates inflammatory signaling, and reduces oxidative DNA damage in breast and liver cancer cells
Authors: Sedat Carkit, Münevver Baran, Nazmiye Bitgen, Gozde Ozge Onder, Damla Gündüz, Arzu Yay
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 20, 2026, 06:45Grant Garcia: Why Does a Blood Clot Diagnosis Immediately End an Athlete’s Season?
-
Oct 20, 2026, 06:35Parag Tamhankar: Landmark Study Reveals Genetic Spectrum and Targeted Therapies for ALPS in the Indian Population
-
Oct 20, 2026, 06:26Nina Houben: Neonatal Blood Transfusion Symposium and PhD Defense
-
Oct 20, 2026, 05:46Jan T. Kielstein: DNP Poisoning and Hemoadsorption The Limits of Rescue Therapy
-
Oct 20, 2026, 05:33Giulia Di Paolo: Connecting Plasma Donation to the Patients Who Depend on It
-
Oct 20, 2026, 05:20James Knowles: Exploring Plasma Manufacturing and Strengthening Industry Collaboration
-
Oct 20, 2026, 05:11Giuseppe Lippi։ Understanding Liver Test Abnormalities After AAV Gene Therapy
-
Oct 20, 2026, 05:02Sanam Loghavi: Test Your Hematology Knowledge at ASH 2026!
-
Oct 20, 2026, 04:13Ifeanyichukwu Ifechidere: DOACs Are Not the Answer to Every Anticoagulation Question